Trazodone Use During Breastfeeding
Trazodone can be used during breastfeeding with appropriate monitoring, as infant exposure through breast milk is very low and limited postmarketing data have not identified adverse effects on breastfed infants.
Evidence from FDA Drug Label
The FDA label for trazodone explicitly addresses breastfeeding 1. The label states that trazodone passes into breast milk, but limited data from postmarketing reports have not identified an association of adverse effects on the breastfed child. The label recommends that "the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Trazodone Hydrochloride Tablets and any potential adverse effects on the breastfed child" 1.
Pharmacokinetic Data Supporting Low Infant Exposure
The most compelling evidence comes from actual measurement of drug transfer:
A 1986 study demonstrated a milk/plasma ratio of only 0.142, meaning trazodone concentrations in breast milk are approximately 14% of maternal blood levels 2. Based on typical infant milk intake, babies would be exposed to less than 0.005 mg/kg compared to 0.77 mg/kg for mothers—representing minimal exposure 2.
A 2021 pharmacokinetic case study confirmed these findings, showing trazodone and its active metabolite (mCPP) concentrations in breast milk of 50.2 ng/mL and 3.2 ng/mL respectively, collected 7.2 hours after maternal dosing of 50 mg 3. The infant in this case developed normally with no drug-related adverse effects at 1-, 3-, and 6-month follow-ups 3.
Clinical Recommendations
Use the lowest effective dose for the shortest duration necessary. While trazodone is not specifically mentioned in the 2020 Association of Anaesthetists guideline on breastfeeding [@1-10@], the general principle for sedative and psychotropic medications applies: prioritize drugs with established safety profiles and monitor infants for sedation, drowsiness, and poor feeding.
Practical Monitoring Approach:
Observe the infant for:
- Unusual drowsiness or sedation
- Poor feeding or decreased alertness
- Respiratory changes
Timing considerations: Peak milk concentrations occur approximately 1.5 hours after maternal dosing 3. If concerned, mothers could time breastfeeding to occur before taking trazodone or several hours after dosing when milk levels are lower.
Dose considerations: The available data primarily involve low doses (50 mg). Higher doses may warrant closer infant monitoring, though no specific threshold has been established.
Important Caveats
The evidence base remains limited. Most data comes from case reports and small studies rather than large-scale trials 3, 2, 4. However, the consistent finding across available studies is that infant exposure is very low and adverse effects have not been documented in the limited postmarketing surveillance 1.
Premature infants or those with hepatic/renal dysfunction may be more vulnerable to any drug exposure through breast milk, as their drug metabolism and clearance mechanisms are immature 4.
Untreated maternal depression poses its own risks to both mother and infant. The decision to use trazodone should weigh the benefits of treating maternal depression against the theoretical risks of low-level infant exposure 1.
Alternative Considerations
If there are concerns about trazodone use, sertraline and paroxetine are considered preferred SSRIs during breastfeeding due to lower milk concentrations and more extensive safety data 5. However, trazodone's unique sedative properties at low doses (25-75 mg) make it particularly useful for maternal insomnia and anxiety, conditions where SSRIs may be less effective 6.